View in EDS HTML Full Text PDF Full Text

Clinical Trial to Assess the Safety and Tolerability of Anti‐IL 23 Monoclonal Antibody Guselkumab in Patients With Alcohol‐Associated Liver Disease.

Saved in:
Bibliographic Details
Title: Clinical Trial to Assess the Safety and Tolerability of Anti‐IL 23 Monoclonal Antibody Guselkumab in Patients With Alcohol‐Associated Liver Disease.
Authors: Diaz, Luis Antonio1,2 (AUTHOR), Morris, Sheldon1 (AUTHOR), Dave, Shravan1 (AUTHOR), Kim, Susy M.1 (AUTHOR), Sarik, Wathnita1 (AUTHOR), Richards, Lisa1 (AUTHOR), Madamba, Egbert1 (AUTHOR), Bettencourt, Ricki1 (AUTHOR), Fulinara, Christian3 (AUTHOR), Pham, Thuy3 (AUTHOR), Miller, Grant4 (AUTHOR), Carvalho‐Gontijo Weber, Raquel4 (AUTHOR), Momper, Jeremiah D.1,5 (AUTHOR), He, Feng6 (AUTHOR), Jain, Sonia6 (AUTHOR), Jamieson, Catriona1 (AUTHOR), Kisseleva, Tatiana1,7 (AUTHOR), Brenner, David1,4 (AUTHOR), Loomba, Rohit1 (AUTHOR) roloomba@health.ucsd.edu
Source: Alimentary Pharmacology & Therapeutics. Apr2025, Vol. 61 Issue 7, p1140-1151. 12p.
Database: Academic Search Ultimate
Full text is not displayed to guests.
Description
ISSN:02692813
DOI:10.1111/apt.70026